Fenofibrate/pitavastatin - Hanlim Pharmaceutical
Alternative Names: HL-PIF; Livasupril; Pitavastatin/fenofibrate; STAFEN; STAFEN Cap - Hanlim PharmaceuticalLatest Information Update: 08 Mar 2021
At a glance
- Originator Hanlim Pharmaceutical
- Class Antihyperlipidaemics; Benzophenones; Butyric acids; Carboxylic acids; Cyclopropanes; Fibric acid derivatives; Fluorobenzenes; Propionates; Quinolines; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia
Most Recent Events
- 29 Jan 2019 Chemical structure information added
- 01 Jan 2018 Hanlim Pharm completes a phase III trial in Hyperlipidemia in South Korea (NCT03618797)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Undefined(In volunteers) in South Korea (PO, Capsule)